Q1 2025 Fennec Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Fennec Pharmaceuticals Inc (FENC) reported an 18% growth in net product sales for Q1 2025 compared to the same period last year, indicating strong market performance.
- The company has successfully implemented a sophisticated targeting model to enhance field execution and engagement, focusing on high-prescribing cisplatin users.
- PEDMARK has been integrated into treatment plans at major institutions like Tampa General Hospital and City of Hope, validating its clinical utility.
- Fennec Pharmaceuticals Inc (FENC) has launched PEDMARK commercially in Germany and the UK, with positive early indicators of engagement and uptake.
- The company is actively enhancing its Fennec HEARS patient support program to improve access, streamline reimbursement, and expand home nursing capabilities, which has led to improved patient adherence.
- The company recorded a cash burn of approximately $4 million in Q1 2025, indicating ongoing financial pressure.
- General and administrative expenses increased quarter-over-quarter, largely due to non-cash-based stock compensation.
- Despite growth, the company is not yet at a cash flow breakeven point, requiring $8.5 million to $9 million in sales to achieve this.
- There is still a significant lack of awareness about the impact of ototoxicity and PEDMARK among some healthcare providers.
- The company faces challenges in ensuring adherence to PEDMARK treatment, with only about 50% of patients completing the full course.
Good morning, ladies and gentlemen, and welcome to Fennec Pharmaceuticals' first-quarter 2025 earnings and corporate update conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
Now I would like to turn the conference over to Fennec's Chief Financial Officer, Robert Andrade.
Thank you, operator, and good morning, everyone. We appreciate you joining us today for Fennec Pharmaceuticals' first-quarter 2025 earnings conference call, in which we will review our financial results as well as provide a general business update.
Joining me from Fennec this morning is our Chief Executive Officer and Board member, Jeff Hackman. Before we begin, I would like to remind you that during this call, the company will be making forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward-looking statements.
Reference to these risks and uncertainties
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
